PARIS, Sept 11 (Reuters) - Drugmakers Sanofi and Regeneron announced on Monday positive results for their dupilumab product, which helps treat allergic inflammation.
The companies said that a pivotal Phase 3 ‘Liberty Asthma Quest’ study of dupilumab in a broad population of patients with uncontrolled, persistent asthma had met its two primary endpoints.
They said that it had been found that dupilumab, when added to standard therapies, reduced severe asthma attacks and improved lung function.
“The positive data from this large second pivotal trial in uncontrolled persistent asthma, following the positive results of dupilumab in atopic dermatitis, further support this view in our opinion. We will work diligently with health authorities to bring this new application of dupilumab to the patients who most need it,” said Elias Zerhouni, managing director and president of global research and development at Sanofi. (Reporting by Sudip Kar-Gupta; Editing by Biju Dwarakanath)
Our Standards: The Thomson Reuters Trust Principles.